###begin article-title 0
GSK-3beta Controls Osteogenesis through Regulating Runx2 Activity
###end article-title 0
###begin p 1
Conceived and designed the experiments: HK FK UC. Performed the experiments: NK FK SO MH. Analyzed the data: FK KN. Contributed reagents/materials/analysis tools: JW NK SO HC YA. Wrote the paper: FK.
###end p 1
###begin p 2
###xml 460 465 454 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Runx2</italic>
###xml 254 258 <span type="species:ncbi:10090">mice</span>
###xml 476 480 <span type="species:ncbi:10090">mice</span>
Despite accumulated knowledge of various signalings regulating bone formation, the molecular network has not been clarified sufficiently to lead to clinical application. Here we show that heterozygous glycogen synthase kinase-3beta (GSK-3beta)-deficient mice displayed an increased bone formation due to an enhanced transcriptional activity of Runx2 by suppressing the inhibitory phosphorylation at a specific site. The cleidocranial dysplasia in heterozygous Runx2-deficient mice was significantly rescued by the genetic insufficiency of GSK-3beta or the oral administration of lithium chloride, a selective inhibitor of GSK-3beta. These results establish GSK-3beta as a key attenuator of Runx2 activity in bone formation and as a potential molecular target for clinical treatment of bone catabolic disorders like cleidocranial dysplasia.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 399 402 399 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Karsenty1">[1]</xref>
###xml 551 554 551 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Ducy1">[2]</xref>
###xml 555 558 555 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Otto1">[4]</xref>
###xml 687 690 687 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Otto1">[4]</xref>
###xml 510 514 <span type="species:ncbi:10090">mice</span>
###xml 623 629 <span type="species:ncbi:9606">humans</span>
###xml 634 638 <span type="species:ncbi:10090">mice</span>
Bone formation is such a dynamic and intricate process that its perturbation leads to a variety of bone catabolic disorders including skeletal malformations and osteoporosis. Accumulated molecular evidence has revealed the involvements of a number of signalings in this process: Runx2, Wnt, insulin/phosphatidylinositol 3-kinase (PI3K)/Akt, bone morphogenetic proteins/Smads, hedgehog, Osterix, etc [1]. Among them, Runx2 is known to be essential for osteoblastic differentiation, because its null mutation in mice exhibited the complete lack of bone [2]-[4]. The heterozygous loss leads to cleidocranial dysplasia in both humans and mice, which is attributed to impaired bone formation [4]. Despite accumulated knowledge of these osteogenic siganling molecules, the interactions among them to form the molecular network of bone formation have not been clarified sufficiently to lead to epochal therapeutics to treat bone disorders like cleidocranial dysplasia.
###end p 4
###begin p 5
###xml 393 396 386 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Doble1">[5]</xref>
###xml 514 517 501 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Patel1">[6]</xref>
###xml 577 580 564 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Gong1">[7]</xref>
###xml 581 585 568 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Krishnan1">[13]</xref>
###xml 606 613 593 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 706 710 <span type="species:ncbi:10090">mice</span>
Glycogen synthase kinase-3 (GSK-3) was originally identified as a serine/threonine kinase involved in the regulation of glycogen deposition. The enzyme which comprises two isoforms, GSK-3alpha and GSK-3beta, has since been implicated in many different biological processes including developmental patterning and cell survival as a regulatory switch that integrates numerous signaling pathways [5]. Among them, GSK-3beta is known to be a key negative regulator of canonical Wnt/beta-catenin and PI3K/Akt signalings [6], both of which have been reported to induce bone formation [7]-[13]. To investigate the in vivo role of GSK-3beta, the present study analyzed the skeletal phenotype of GSK-3beta-deficient mice, and investigated the underlying molecular mechanism.
###end p 5
###begin title 6
Results
###end title 6
###begin title 7
###xml 56 60 <span type="species:ncbi:10090">mice</span>
Increased bone mass in heterozygous Gsk-3beta-deficient mice
###end title 7
###begin p 8
###xml 101 106 98 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 126 130 120 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Hoeflich1">[14]</xref>
###xml 156 166 150 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3&#946;-</italic>
###xml 177 182 168 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 186 189 174 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 269 279 257 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3&#946;-</italic>
###xml 290 295 275 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 299 302 281 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 410 417 392 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g001">Fig. 1A</xref>
###xml 556 561 538 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 565 568 544 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 630 635 609 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 639 642 615 618 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 655 665 631 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g001">Fig. 1B, C</xref>
###xml 928 935 901 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g001">Fig. 1D</xref>
###xml 1041 1046 1014 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 1050 1053 1020 1023 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 1134 1141 1104 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g001">Fig. 1E</xref>
###xml 1270 1277 1237 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g001">Fig. 1F</xref>
###xml 1604 1609 1567 1572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 1613 1616 1573 1576 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 1623 1630 1583 1590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g001">Fig. 1G</xref>
###xml 121 125 <span type="species:ncbi:10090">mice</span>
###xml 191 195 <span type="species:ncbi:10090">mice</span>
###xml 304 308 <span type="species:ncbi:10090">mice</span>
###xml 569 573 <span type="species:ncbi:10090">mice</span>
###xml 1054 1058 <span type="species:ncbi:10090">mice</span>
###xml 1617 1621 <span type="species:ncbi:10090">mice</span>
To investigate the physiological role of GSK-3beta in skeletal tissues, we examined the phenotype of Gsk-3beta-deficient mice [14]. Although the homozygous Gsk-3beta-deficient (Gsk-3beta-/-) mice died in late embryogenesis due to severe liver dysfunction, heterozygous Gsk-3beta-deficient (Gsk-3beta+/-) mice developed and grew normally without disorders in major organs nor gross abnormality in the skeleton (Fig. 1A). However, the radiographs of the entire femurs and the three-dimensional computed tomography (3-D CT) of the distal femurs revealed that Gsk-3beta+/- mice showed an increased bone mass compared to the wild-type Gsk-3beta+/+ littemates (Fig. 1B, C). Histological examination of the proximal tibiae confirmed the increases in both trabecular and cortical bones without abnormality in the growth plate, indicating that bone metabolism, not cartilage metabolism, was affected by the GSK-3beta haploinsufficiency (Fig. 1D). In the bone histomorphometric analysis, the increased trabecular bone volume and cortical thickness in Gsk-3beta+/- mice were accompanied by significant increases in parameters of bone formation (Fig. 1E). Bone resorption parameters were also enhanced by the GSK-3beta insufficiency, although weaker than bone formation parameters (Fig. 1F). Osteoclasts are known to be derived from hematopoietic cells and require cell-cell interactions with osteoblasts or stromal cells for differentiation. In the co-culture of calvarial primary osteoblasts and bone marrow macrophages (BMMphi), osteoclastogenesis was enhanced when osteoblasts, but not BMMphi, were derived from Gsk-3beta+/- mice (Fig. 1G), implicating that the enhanced bone resorption was due to the secondary effect of osteoblast dysfunction, but not the intrinsic defects of osteoclastic cells.
###end p 8
###begin title 9
###xml 112 115 106 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 103 115 100 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3&#946;<sup>+/+</sup></italic>
###xml 129 132 120 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 120 132 114 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3&#946;<sup>+/&#8211;</sup></italic>
Increased bone mass due to the GSK-3beta insufficiency by radiological and histological comparisons of Gsk-3beta+/+ and Gsk-3beta+/- littermates at 12 weeks of age.
###end title 9
###begin p 10
###xml 1098 1100 1084 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 1108 1110 1094 1096 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 1119 1124 1105 1110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 1128 1131 1111 1114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1305 1310 1286 1291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 1314 1317 1292 1295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1321 1326 1299 1304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 1330 1333 1305 1308 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 1485 1487 1454 1456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 1496 1501 1465 1470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 1505 1508 1471 1474 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1511 1516 1477 1482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 1520 1523 1483 1486 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1078 1082 <span type="species:ncbi:10090">mice</span>
###xml 1334 1338 <span type="species:ncbi:10090">mice</span>
(A) Plain X-ray of the whole body. (B) Plain X-ray of the entire femur. (C) 3D-CT image of the distal femur. (D) von Kossa staining of the proximal tibia (bar, 200 microm) and toluidine blue staining of the growth plate indicated by the inset box above (bar, 20 microm). (E) Histomorphometric analyses of bone volume and bone formation parameters in the proximal tibia. BV/TV, trabecular bone volume per tissue volume; C.Th, cortical thickness; Ob.S/BS, osteoblast surface per trabecular bone surface; Ob.S/B.Pm, osteoblast surface per trabecular bone perimeter; MAR, mineral apposition rate; BFR/BS, bone formation rate per trabescular bone surface. Lower right panel shows fluorescent micrographs of calcein-labeled mineralization fronts of the trabecular bones (bar, 10 microm). (F) Histomorphometric analyses of bone resorption parameters in the proximal tibia. N.Oc/B.Pm, number of osteoclasts per 100 mm of bone perimeter; Oc.S/BS, osteoclast surface per bone surface; ES/BS, eroded surface per bone surface. For (E) and (F), data are mean (bars)+/-SEM (error bars) of 10 mice per genotype. *P<0.05, **P<0.01 vs. Gsk-3beta+/+. (G) Formation of TRAP-positive multinucleated osteoclasts by the co-culture of calvarial primary osteoblasts (POB) and bone marrow macrophages (BMMphi) derived from either Gsk-3beta+/+ or Gsk-3beta+/- mice. Representative pictures (left; bar, 200 microm) and the number of osteoclasts expressed as mean (bars)+/-SEM (error bars) of 8 wells per group. *P<0.05 vs. Gsk-3beta+/+ X Gsk-3beta+/+.
###end p 10
###begin title 11
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GSK-3</italic>
Suppression of bone formation by GSK-3beta in cultured osteoblasts
###end title 11
###begin p 12
###xml 72 77 72 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 81 84 78 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 103 110 100 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 158 163 155 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 167 170 161 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 196 201 190 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 205 208 196 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 257 262 245 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 266 269 251 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 325 330 310 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 334 337 316 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 382 389 360 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g002">Fig. 2A</xref>
###xml 459 466 437 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g002">Fig. 2B</xref>
###xml 610 615 588 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 619 622 594 597 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 632 639 607 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g002">Fig. 2C</xref>
###xml 944 948 916 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Bialek1">[15]</xref>
###xml 950 957 922 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g002">Fig. 2D</xref>
###xml 1443 1450 1397 1404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g002">Fig. 2E</xref>
###xml 1573 1578 1524 1529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 1582 1585 1530 1533 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1622 1627 1570 1575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 1631 1634 1576 1579 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 1644 1651 1589 1596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g002">Fig. 2F</xref>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
To investigate the mechanism underlying the increased bone formation in Gsk-3beta+/- mice, we compared ex vivo cultures of calvarial osteoblasts derived from Gsk-3beta+/- mice with those from the Gsk-3beta+/+ littermates. The GSK-3beta protein level in the Gsk-3beta+/- osteoblasts was confirmed to be lower than that in the Gsk-3beta+/+, while the GSK-3alpha level was comparable (Fig. 2A). Although cell proliferation was similar between the two genotypes (Fig. 2B), osteoblast differentiation and function determined by alkaline phosphatase (ALP), Alizarin red, and von Kossa stainings were enhanced in the Gsk-3beta+/- culture (Fig. 2C). Real-time RT-PCR analyses revealed that expressions of osteoblastic differentiation markers type I collagen (Col I), osteopontin, ALP, and osteocalcin were up-regulated by the GSK-3beta insufficiency, whereas the differentiation markers of mesenchymal progenitors Twist-1 and Twist-2 were not affected [15] (Fig. 2D). Overexpression of the wild-type GSK-3beta and constitutively active form of GSK-3beta (CA-GSK-3beta) via the adenoviral introduction significantly suppressed bone formation determined by the von Kossa staining and the osteocalcin mRNA level to similar levels in the two genotypes; however, overexpression of the kinase-inactive form of GSK-3beta (KI-GSK-3beta) did not affect it, indicating that kinase activity of GSK-3beta is essential for its inhibitory action on bone formation (Fig. 2E). Contrarily, addition of lithium chloride or SB216763, selective inhibitors of GSK-3beta, promoted bone formation in the Gsk-3beta+/+ culture to the level similar to the Gsk-3beta+/- culture (Fig. 2F).
###end p 12
###begin title 13
Suppression of bone formation by GSK-3beta in cultured osteoblasts.
###end title 13
###begin p 14
###xml 72 77 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 81 84 71 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 89 94 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 98 101 85 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 715 720 695 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 724 727 701 704 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 759 761 736 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 770 775 747 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 779 782 753 756 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1397 1402 1350 1355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 1406 1409 1356 1359 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1441 1443 1391 1393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 1514 1516 1461 1463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
(A) Expressions of GSK-3beta and GSK-3alpha in calvarial osteoblasts of Gsk-3beta+/+ and Gsk-3beta+/- littermates determined by immunoblot analysis with beta-actin as a loading control. (B) Cell proliferation determined by the XTT assay in osteoblasts during 8 days of culture. Data are the mean (symbols)+/-SEM (error bars) of 6 dishes/genotype. (C) ALP (top), Alizarin red (middle), and von Kossa (bottom) stainings in osteoblasts cultured for 2 weeks. (D) mRNA levels of type I collagen (Col I), osteopontin, ALP, osteocalcin, Twist-1 and Twist-2, determined by real-time RT-PCR analysis in osteoblasts cultured for 2 weeks. Data are mean (bars)+/-SEM (error bars) of the relative amount compared to that of the Gsk-3beta+/+ culture 6 wells per genotype. *P<0.01 vs. Gsk-3beta+/+. (E) von Kossa staining (top) and osteocalcin mRNA level determined by real-time RT-PCR analysis (bottom) of osteoblasts transfected with the adenovirus expressing GFP, wild-type GSK-3beta, constitutively active GSK-3beta (CA-GSK-3beta), or kinase-inactive GSK-3beta (KI-GSK-3beta), and cultured for 2 weeks. (F) von Kossa staining (top) and osteocalcin mRNA level (bottom) of osteoblasts cultured with and without lithium chloride (LiCl, 16 mM) or SB216763 (10 microM) for 2 weeks. For (E) and (F), the mRNA levels are mean (bars)+/-SEM (error bars) of the relative amount of mRNA compared to that of the control Gsk-3beta+/+ culture of 6 wells per group. *P<0.01, significant stimulation by the genetic GSK-3beta insufficiency. #P<0.01, significant effects by the adenoviral overexpression or the GSK-3beta inhibitors.
###end p 14
###begin title 15
Inactivation through phosphorylation of Runx2 by GSK-3beta
###end title 15
###begin p 16
###xml 244 247 235 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Doble1">[5]</xref>
###xml 258 265 249 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 361 365 349 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Glass1">[16]</xref>
###xml 474 478 462 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Fujita1">[17]</xref>
###xml 674 681 656 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g003">Fig. 3A</xref>
###xml 821 824 800 803 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 812 824 794 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3&#946;<sup>+/+</sup></italic>
###xml 838 841 814 817 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 829 841 808 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3&#946;<sup>+/&#8211;</sup></italic>
###xml 873 880 849 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g003">Fig. 3B</xref>
###xml 1334 1341 1298 1305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g003">Fig. 3C</xref>
###xml 1402 1409 1366 1373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g003">Fig. 3D</xref>
###xml 1115 1120 <span type="species:ncbi:9606">human</span>
We next examined the molecular mechanism underlying the GSK-3beta inhibition of bone formation. In the two major osteogenic signalings in which GSK-3beta is known to be involved, i.e., the canonical Wnt/beta-catenin and the PI3K/Akt signalings [5]. A recent in vivo study showed that beta-catenin hardly affected osteoblasts through a cell-autonomous mechanism [16]. Considering that the other signaling PI3K/Akt is related to Runx2 transactivation in its osteogenic action [17], we examined the involvement of Runx2 in the GSK-3beta regulation of bone formation. We initially confirmed both GSK-3beta and Runx2 expressions in the calvaria, tibia, and cultured osteoblasts (Fig. 3A). Bone formation determined by von Kossa staining and the osteocalcin mRNA level was enhanced by the Runx2 overexpression in both Gsk-3beta+/+ and Gsk-3beta+/- calvarial osteoblast cultures (Fig. 3B). To examine the regulation of transcriptional activity of Runx2 by GSK-3beta, a luciferase reporter gene construct containing a 1,050 bp osteocalcin gene fragment (1,050 OC-Luc) including the Runx2 binding sites was transfected into human hepatoma HuH-7 cells. The luciferase reporter analysis revealed that the Runx2-dependent transcription was suppressed by the co-expression of wild-type GSK-3beta and CA-GSK-3beta, but not by that of KI-GSK-3beta (Fig. 3C), whereas it was enhanced by lithium chloride and SB216763 (Fig. 3D). Collectively, these data demonstrate that the kinase activity of GSK-3beta suppresses the Runx2 transcriptional activity.
###end p 16
###begin title 17
Suppression of Runx2 transcriptional activity by GSK-3beta.
###end title 17
###begin p 18
###xml 257 262 254 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 266 269 260 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 274 279 268 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 283 286 274 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 488 493 477 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 497 500 483 486 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 541 543 527 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 1400 1402 1365 1367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 76 81 <span type="species:ncbi:10090">mouse</span>
(A) Expressions of GSK-3beta and Runx2 determined by immunoblot analysis in mouse calvaria, tibia, and cultured calvarial primary osteoblasts (POB). (B) von Kossa staining (left) and osteocalcin mRNA level determined by real-time RT-PCR analysis (right) of Gsk-3beta+/+ and Gsk-3beta+/- osteoblasts transfected with the adenovirus expressing GFP or Runx2, and cultured for 2 weeks. The mRNA levels are mean (bars)+/-SEM (error bars) of the relative amount of mRNA compared to that of the Gsk-3beta+/+ with GFP culture of 6 wells per group. *P<0.01, significant stimulation by the Runx2 overexpression. (C) Luciferase reporter analysis of the effects of GSK-3beta overexpression on the Runx2 transcriptional activity. HuH-7 cells were transfected with 1,050 OC-Luc alone or in combination with the plasmid expressing Runx2, and co-transfected with 0.1 or 0.2 microg plasmid expressing wild-type GSK-3beta, CA-GSK-3beta, or KI-GSK-3beta, and cultured for 2 weeks. (D) Luciferase reporter analysis of the effects of GSK-3beta inhibitors on the Runx2 transcriptional activity. HuH-7 cells were transfected with 1,050 OC-Luc alone or with the plasmid expressing Runx2, and cultured in the presence or absence of two doses of lithium chloride (LiCl) or SB21673 for 2 days. For (C) and (D), data are mean (bars)+/-SEM (error bars) of the relative activity compared to control culture of 6 wells per group. *P<0.01 vs. Runx2 alone.
###end p 18
###begin p 19
###xml 297 304 288 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g004">Fig. 4A</xref>
###xml 327 332 318 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 336 339 324 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 344 349 332 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 353 356 338 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 512 515 497 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 553 564 538 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">osteocalcin</italic>
###xml 579 583 564 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Ducy2">[18]</xref>
###xml 956 963 941 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g004">Fig. 4B</xref>
###xml 1008 1013 993 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 1017 1020 999 1002 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 1065 1070 1047 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 1074 1077 1053 1056 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1341 1351 1314 1324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g004">Fig. 4C, D</xref>
###xml 1650 1653 1617 1620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Doble1">[5]</xref>
###xml 2147 2154 2114 2121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g004">Fig. 4E</xref>
###xml 2157 2165 2124 2132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 2277 2284 2241 2248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g004">Fig. 4F</xref>
###xml 2482 2489 2446 2453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g004">Fig. 4G</xref>
###xml 2776 2783 2734 2741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g004">Fig. 4H</xref>
###xml 547 552 <span type="species:ncbi:10090">mouse</span>
To further investigate how GSK-3beta is involved in the Runx2 activity, we examined the effects of CA-GSK-3beta overexpression, lithium chloride treatment, and the genetic GSK-3beta insufficiency on the expression and subcellular localization of Runx2, and found that none altered either of them (Fig. 4A). We then transfected Gsk-3beta+/+ and Gsk-3beta+/- osteoblasts with Runx2, and compared the binding of the nuclear extracts with the oligonucleotide probe of the Runx2 binding sequence, osteoblast-specific cis-acting element 2 (OSE2) of the mouse osteocalcin gene promoter [18], by electrophoretic mobility shift assay (EMSA). We found a complex that was confirmed to represent the Runx2-OSE2 binding, since it diappeared by the addition of 50-fold excess of unlabeled wild-type OSE2 probe, but not by the mutated probe lacking the Runx2 binding sequence, and was undetectable when the nuclear extract from cells without Runx2 transfection was used (Fig. 4B). The specific complex was augmented by the Gsk-3beta+/- nuclear extracts as compared to that by the Gsk-3beta+/+ extracts, indicating that GSK-3beta attenuates the DNA binding activity of Runx2. We then investigated biochemical interactions between Runx2 and GSK-3beta by co-immunoprecipitation assay, which showed the possible direct interaction between these two molecules (Fig. 4C, D). To learn the contribution of the phosphorylation of Runx2 by GSK-3beta to the attenuation of Runx2 transcriptional activity, we generated phosphorylation-deficient mutants of Runx2 by creating three to four amino acid replacements at the five consensus sites for the phosphorylation by GSK-3beta [5]: S92A-S96A-S100A, S369A-S373A-S377A, S389A-T393A-S397A, T394A-S398A-T402A, and T476A-T480A-S484A-S488A. The luciferase reporter analysis using the 1,050 OC-Luc-transfected HuH-7 cells revealed that the phosphorylation-deficient mutant at S369-S373-S377 enhanced the transcriptional activity, while mutations at the other four phosphorylation sites showed comparable activity to the wild-type Runx2, indicating that the specific phosphorylation at S369-S373-S377 suppresses the Runx2 activity (Fig. 4E). In vitro kinase assay confirmed that the Runx2 phosphorylation by GSK-3beta was reduced by the S369-S373-S377 mutation (Fig. 4F). When we compared the DNA binding of nuclear extracts from HeLa cells transfected with wild-type and the S369-S373-S377 mutant Runx2 by EMSA, the mutation enhanced the specific Runx2-DNA binding (Fig. 4G). Finally, the luciferase reporter analysis disclosed that the regulations of Runx2-dependent transcription by gain- and loss-of-functions of GSK-3beta, i.e., suppression by CA-GSK-3beta overexpression and enhancement by lithium chloride, were cancelled by the S369-S373-S377 mutation (Fig. 4H). These lines of results demonstrate that the phosphorylation of Runx2 at S369-S373-S377 by GSK-3beta attenuates the transcriptional activity of Runx2, leading to the suppression of bone formation.
###end p 19
###begin title 20
Inactivation through phosphorylation of Runx2 by GSK-3beta.
###end title 20
###begin p 21
###xml 164 169 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 173 176 170 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 181 186 178 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 190 193 184 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 540 545 529 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 549 552 535 538 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 556 561 542 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 565 568 548 551 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 2099 2101 2077 2079 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 2124 2132 2102 2110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 3089 3091 3056 3058 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
(A) Subcellular nuclear (N) and cytoplasmic (C) localizations of Runx2 by immunoblot analysis (top) and Runx2 mRNA level determined by real-time RT-PCR (bottom) in Gsk-3beta+/+ and Gsk-3beta+/- calvarial osteoblasts overexpressing CA-GSK-3beta or treated with LiCl, and cultured for 3 days. The mRNA levels are mean (bars)+/-SEM (error bars) of the relative amount compared to the control culture of 6 wells per group. (B) EMSA for specific binding (arrowheads) of a labeled OSE2 oligonucleotide probe with the nuclear extracts (N.E.) from Gsk-3beta+/+ or Gsk-3beta+/- osteoblasts overexpressing Runx2. Cold competition (Comp.) was performed with 50-fold excess of unlabeled wild-type OSE2 probe (wt) and the mutated probe lacking the Runx2 binding sequence (mut). For controls, incubations without the probe (the 1st lane) and using nuclear extracts from osteoblasts without Runx2 transfection (the last lane) were performed. (C, D) Co-immunoprecipitation (co-IP) analysis of GSK-3b and Runx2. (C) Whole cell lysate (CL) and co-IP precipitant by anti-FLAG antibody-immobilized beads were immunoblotted with either anti-HA tag or anti FLAG tag antibodies. Filled arrowhead indicates non-specific band, and blank arrowhead indicates specific band. (D) Whole cell lysate (CL) and co-IP precipitant by anti-HA tag antibody or IgG (as a negative control) were immunoblotted with either anti-FLAG tag or anti-HA tag antibodies. (E) Luciferase reporter analysis of the effects of Runx2 mutations at the five consensus sites for the phosphorylation by GSK-3beta on the Runx2 transcriptional activity. Mutations were created by three to four amino acid replacements as follows; S92A-S96A-S100A [M(96)3], S369A-S373A-S377A [M(373)3], S389A-T393A-S397A [M(393)3], T394A-S398A-T402A [M(398)3], and T476A-T480A-S484A-S488A [M(480)4]. HuH-7 cells were transfected with 1,050 OC-Luc alone or in combination with the plasmids expressing wild-type Runx2 (WT) or the mutants above, then cultured for 2 days. Data are mean (bars)+/-SEM (error bars) of the relative activity compared to control of 6 wells per group. *P<0.01 vs. WT-Runx2. (F) In vitro kinase assay. WT-Runx2 and M(373)3-Runx2 proteins were extracted by immunoprecipitation of the overexpresssing HeLa cells, and were incubated with recombinant GSK-3beta. Reaction products were analyzed by immunoblotting using an antibody to phosphoserine. (G) EMSA for specific binding (arrowheads) of a labeled OSE2 probe with the nuclear extracts (N.E.) from HeLa cells transfected with wild-type Runx2 (WT) and M(373)3 Runx2 (M). Cold competition (Comp.) was performed as above. (H) Luciferase reporter analysis of the effects of GSK-3beta signaling on the Runx2 transcriptional activity induced by WT-Runx2 and M(373)3-Runx2. HuH-7 cells were transfected with 1,050 OC-Luc alone or in combination with the plasmid expressing WT-Runx2 or M(373)3-Runx2 in the presence or absence of CA-GSK-3beta overexpression or LiCl, then cultured for 2 days. Data are mean (bars)+/-SEM (error bars) of the relative activity compared to control of 6 wells per group. *P<0.01, significant effect of CA-GSK-3beta overexpression or LiCl.
###end p 21
###begin title 22
Rescue of cleidocranial dysplasia by suppressing GSK-3beta
###end title 22
###begin p 23
###xml 27 35 27 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 117 124 114 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 146 149 140 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 137 149 134 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3&#946;<sup>+/&#8722;</sup></italic>
###xml 154 159 148 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Runx2</italic>
###xml 159 162 153 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 231 234 222 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 241 244 232 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 222 244 216 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3&#946;<sup>+/&#8722;</sup>; Runx2<sup>+/&#8722;</sup></italic>
###xml 297 302 288 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Runx2</italic>
###xml 302 305 293 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 458 461 449 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Komori1">[3]</xref>
###xml 463 466 454 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Otto1">[4]</xref>
###xml 485 488 473 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 476 488 467 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3&#946;<sup>+/&#8722;</sup></italic>
###xml 530 533 515 518 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 540 543 525 528 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 521 543 509 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3&#946;<sup>+/&#8722;</sup>; Runx2<sup>+/&#8722;</sup></italic>
###xml 636 639 621 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 631 639 616 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Runx2<sup>+/&#8722;</sup></italic>
###xml 646 656 631 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g005">Fig. 5A, B</xref>
###xml 163 167 <span type="species:ncbi:10090">mice</span>
###xml 216 220 <span type="species:ncbi:10090">mice</span>
###xml 306 310 <span type="species:ncbi:10090">mice</span>
###xml 324 329 <span type="species:ncbi:9606">human</span>
###xml 489 493 <span type="species:ncbi:10090">mice</span>
###xml 544 548 <span type="species:ncbi:10090">mice</span>
###xml 640 644 <span type="species:ncbi:10090">mice</span>
To investigate whether our in vitro finding on the molecular interaction between GSK-3beta and Runx2 is reproducible in vivo, we crossed Gsk-3beta+/- and Runx2+/- mice to generate the compound heterozygous deficient mice (Gsk-3beta+/-; Runx2+/-), and analyzed the skeletal phenotypes of neonates. Runx2+/- mice, a model for human cleidocranial dysplasia, showed delayed closure of the fontanelle and hypoplasia of the clavicle due to impaired bone formation [3], [4], whereas Gsk-3beta+/- mice had no such abnormalities. Gsk-3beta+/-; Runx2+/- mice exhibited significant rescue of the both fontanelle and clavicle abnormalities of Runx2+/- mice (Fig. 5A, B).
###end p 23
###begin title 24
Genetic and pharmacological rescue of cleidocranial dysplasia by suppressing GSK-3beta.
###end title 24
###begin p 25
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 40 43 37 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 45 50 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 54 57 48 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 59 64 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Runx2</italic>
###xml 64 67 58 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 73 78 67 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 82 85 73 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 85 92 76 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">; Runx2</italic>
###xml 92 95 83 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 402 407 393 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 411 414 399 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 486 491 474 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Runx2</italic>
###xml 491 494 479 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 541 546 529 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 550 553 535 538 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 553 560 538 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">; Runx2</italic>
###xml 560 563 545 548 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 728 733 711 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Runx2</italic>
###xml 733 736 716 719 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 759 761 742 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 564 568 <span type="species:ncbi:10090">mice</span>
###xml 742 746 <span type="species:ncbi:10090">mice</span>
(A) Calvarias and clavicles of Gsk-3beta+/+, Gsk-3beta+/-, Runx2+/-, and Gsk-3beta+/-; Runx2+/- neonates (0-day) stained with Alizarin red and Alcian blue (bars, 3 mm for calvaria and 0.5 mm for clavicle). (B) Quantitative analyses using the NIH image of the anterior fontanelle area and the clavicle length of the four genotypes. (C) Plain radiographs at 3 weeks of age of the skulls and clavicles of Gsk-3beta+/+ with and without LiCl administration from E7.5 to 3 weeks after birth, Runx2+/- with and without the LiCl administration, and Gsk-3beta+/-; Runx2+/- mice. (D) Quantitative analyses using the NIH image of the five groups. For (B) and (D), data are mean (bars)+/-SEM (error bars) of the relative amount compared to Runx2+/- of 6 mice per group. *P<0.01, significant rescue by genetic GSK-3beta insufficiency or LiCl.
###end p 25
###begin p 26
###xml 222 230 216 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 235 242 229 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 242 246 236 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Davies1">[19]</xref>
###xml 247 251 241 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-DeSarno1">[21]</xref>
###xml 414 417 408 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Otto1">[4]</xref>
###xml 870 873 864 867 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 865 873 859 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Runx2<sup>+/&#8722;</sup></italic>
###xml 928 931 919 922 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 938 941 929 932 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 919 941 913 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3&#946;<sup>+/&#8722;</sup>; Runx2<sup>+/&#8722;</sup></italic>
###xml 948 958 939 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000837-g005">Fig. 5C, D</xref>
###xml 605 609 <span type="species:ncbi:10090">mice</span>
###xml 723 729 <span type="species:ncbi:9606">humans</span>
###xml 874 878 <span type="species:ncbi:10090">mice</span>
###xml 942 946 <span type="species:ncbi:10090">mice</span>
Since this finding indicates the physiological interaction of GSK-3beta with Runx2 function, we next examined a possible pharmacological intervention by lithium chloride that is reported to inhibit GSK-3beta activity both in vitro and in vivo[19]-[21]. Because Runx2 is initially detected during embryogenesis at E9.5 in the notochord and at E10.5 in the mesoderm that is destined to develop to the shoulder bones [4], we administered lithium chloride to the embryos through pregnant and lactating dams from E7.5 to 3 weeks of age before weaning. We confirmed that the serum lithium concentrations of the mice treated with this regimen ranged from 0.66 to 0.70 mM, which falls on the lower side of the therapeutic range in humans (0.5-1.5 mM). Here again, the lithium chloride administration succeeded in restoring both fontanelle and clavicle abnormalities in the Runx2+/- mice, similarly to the genetic rescue in the Gsk-3beta+/-; Runx2+/- mice (Fig. 5C, D), raising the possibility that pharmacological intervention such as lithium chloride administration may clinically be useful for preventing cleidocranial dysplasia.
###end p 26
###begin title 27
Discussion
###end title 27
###begin title 28
GSK-3beta as a negative regulator of osteogenesis
###end title 28
###begin p 29
###xml 12 19 12 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 24 32 24 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 647 651 629 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Westendorf1">[22]</xref>
###xml 831 834 813 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Gong1">[7]</xref>
###xml 835 838 817 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Boyden1">[9]</xref>
###xml 840 844 822 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Bennett1">[23]</xref>
###xml 1052 1056 1031 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-ClementLacroix1">[24]</xref>
###xml 1478 1482 1445 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Day1">[25]</xref>
###xml 1483 1487 1450 1454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Hu1">[27]</xref>
###xml 1755 1759 1719 1723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Glass1">[16]</xref>
###xml 2124 2129 2079 2084 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 2133 2136 2085 2088 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 2180 2184 2132 2136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-ClementLacroix1">[24]</xref>
###xml 815 819 <span type="species:ncbi:10090">mice</span>
###xml 824 830 <span type="species:ncbi:9606">humans</span>
###xml 952 956 <span type="species:ncbi:10090">mice</span>
###xml 2137 2141 <span type="species:ncbi:10090">mice</span>
###xml 2175 2179 <span type="species:ncbi:10090">mice</span>
The present in vivo and in vitro studies demonstrated that the suppression of GSK-3beta in osteoblasts enhanced bone formation through a cell-autonomous mechanism. GSK-3beta is a well-known negative regulator of the canonical Wnt/beta-catenin signaling in that it induces proteasome degradation of beta-catenin in the absence of the Wnt ligands. Binding of the Wnt ligands to the membrane frizzled receptor and low-density lipoprotein receptor-related protein 5 and 6 (LRP5/6) co-receptors inhibits GSK-3beta, causing the stabilization of beta-catenin which then translocates into the nucleus to activate the target genes like T cell factor (TCF) [22]. The Wnt signaling is known to be critical for maintaining bone mass, since gain- and loss- of functions of Lrp5 or Wnt10b positively correlated with bone mass in mice and humans [7]-[9], [23]. Furthermore, a recent study showing that lithium chloride increased bone formation even in Lrp5-deficient mice indicates that GSK-3beta acts downstream of Lrp5 in the osteogenic action of the Wnt signaling [24]. Regarding the possibility of beta-catenin being the target molecule of the GSK-3beta action, recent reports on loss- and gain-of-functions of beta-catenin have provided compelling evidence that beta-catenin represents a differentiation switch of mesenchymal progenitors for inducing osteoblastic differentiation and suppressing chondrocytic differentiation at an early stage of skeletal development during embryogenesis [25]-[27]. In osteoblastic cells, however, beta-catenin together with its target TCF proteins hardly affected their osteogenic function through a cell-autonomous mechanism, but regulated osteoblast expression of osteoprotegerin, a major inhibitor of osteoclast differentiation [16], indicating that osteoanabolic action of beta-catenin is due to the decrease in osteoclastic bone resorption, but not due to the increase in bone formation. Hence, we hereby propose that the enhancement of bone formation by the GSK-3beta suppression is mainly dependent on Runx2 rather than beta-catenin. In addition, because the histomorphometric analyses of the Gsk-3beta+/- mice and the lithium chloride-treated mice [24] showed an increase in bone formation parameters, but not a decrease in bone resorption parameters, we assume that the bone anabolic action of the GSK-3beta suppression is mediated by the Runx2 signaling for bone formation rather than the beta-catenin signaling for bone resorption. The contribution and relationship between Runx2 and beta-catenin as downstream signalings for the osteoanabolic action of the Wnt/Lrp5 should be further studied to elucidate the cellular and molecular network underlying the regulation of bone metabolism by the entire Wnt pathway.
###end p 29
###begin title 30
Attenuation of Runx2 by GSK-3beta
###end title 30
###begin p 31
###xml 78 79 74 75 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 80 81 76 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 435 439 423 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Komori2">[28]</xref>
###xml 769 774 754 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX2</italic>
###xml 811 815 796 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Wee1">[29]</xref>
###xml 1331 1335 1313 1317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Selvamurugan1">[30]</xref>
###xml 1459 1463 1441 1445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Xiao1">[31]</xref>
###xml 1464 1468 1446 1450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Kim1">[33]</xref>
###xml 1631 1635 1613 1617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Ito1">[34]</xref>
###xml 763 768 <span type="species:ncbi:9606">human</span>
###xml 1211 1216 <span type="species:ncbi:10090">mouse</span>
A variety of hormones, cytokines and signaling molecules such as 1alpha,25(OH)2D3, tumor necrosis factor-alpha, fibroblast growth factor (FGF)-2, glucocorticoids, growth hormone, Akt, Stat1 & 3, Twist, Src/Yes, Dlx3, Msx2, PPARgamma, and histone acetylases 3 & 4 have been reported to regulate Runx2 in its expression, subcellular localization, DNA binding, and transcriptional activity, although the mechanisms remain largely unknown [28]. The present study showed that GSK-3beta inhibited the DNA binding and transcriptional activity through the S369-S373-S377 phosphorylation of the Runx protein. Regulation of Runx2 activity through its phosphorylation has been reported by phosphorylation-deficient mutagenesis at two conserved serines, S104 and S451 of the human RUNX2 gene in distinct functional aspects [29]. The S104 phosphorylation is involved in the heterodimerization with the partner subunit PEBP2beta, which enhances the transcriptional activity of RUNX2. On the other hand, the phosphorylation of S451 that resides within the C-terminal transcription inhibition domain of RUNX2 attenuates its transactivity. The consensus site T341 for the phosphorylation by PKA in the transactivation domain of mouse Runx2 is shown to be responsible for the induction of Runx2 transcriptional activity by parathyroid hormone (PTH) [30]. In addition, FGF-2 induces the Runx2 activity through phosphorylation of distinct consensus sites of ERK and PKC pathways [31]-[33]. Meanwhile, the present S369-S373-S377 is located in the negative regulatory region of DNA binding that masks the Runt domain and prevents it from binding to DNA [34]. Hence, the suppression of GSK-3beta may relieve the GSK-3beta-dependent phosphorylation of the negative regulatory region of Runx2, resulting in enhancement of DNA binding ability and transcriptional activity.
###end p 31
###begin p 32
###xml 81 85 81 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Canalis1">[35]</xref>
###xml 87 91 87 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Thrailkill1">[36]</xref>
###xml 300 305 300 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Irs-1</italic>
###xml 307 316 307 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Irs-2, or</italic>
###xml 322 326 322 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Akt1</italic>
###xml 331 335 331 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Akt2</italic>
###xml 380 384 380 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Ogata1">[11]</xref>
###xml 386 390 386 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Akune1">[12]</xref>
###xml 392 396 392 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Peng1">[37]</xref>
###xml 506 510 506 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Fujita1">[17]</xref>
###xml 825 829 822 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Cross1">[38]</xref>
###xml 375 379 <span type="species:ncbi:10090">mice</span>
Insulin and insulin-like growth factor-I function as potent osteoanabolic agents [35], [36] via the activation of their common signaling molecules insulin receptor substrate (IRS)-1, IRS-2, and the subsequent PI3K/Akt. In fact, we and others previously reported that the loss-of-function mutation of Irs-1, Irs-2, or both Akt1 and Akt2 causes impairment of bone formation in mice [11], [12], [37]. As the target of this pathway, a recent study has shown that Akt enhanced transcriptional activity of Runx2 [17]. However, despite the fact that Akt is a serine-threonine kinase, the study failed to show the direct phosphorylation of Runx2 by Akt, and there was no consensus site for the phosphorylation by Akt in the Runx2 sequence. On the other hand, Akt is known to phosphorylate GSK-3beta at Ser9, causing the inactivation [38]. We therefore speculate that the osteoanabolic action of the insulin/IRS/Akt pathway might also be mediated by the Runx2 phosphorylation by GSK-3beta.
###end p 32
###begin title 33
GSK-3beta as a potent therapeutic target for CCD and osteoporosis
###end title 33
###begin p 34
###xml 460 464 454 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-ClementLacroix1">[24]</xref>
###xml 671 675 658 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Krishnan1">[13]</xref>
###xml 845 849 832 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Neer1">[39]</xref>
###xml 1257 1261 1238 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Cohen1">[40]</xref>
###xml 278 282 <span type="species:ncbi:10090">mice</span>
###xml 421 425 <span type="species:ncbi:10090">mice</span>
###xml 455 459 <span type="species:ncbi:10090">mice</span>
###xml 661 664 <span type="species:ncbi:10116">rat</span>
###xml 718 723 <span type="species:ncbi:9606">human</span>
###xml 836 844 <span type="species:ncbi:9606">patients</span>
###xml 1222 1230 <span type="species:ncbi:9606">patients</span>
The cleidocranial dysplasia phenotype by the Runx2 insufficiency was significantly rescued not only by the genetic suppression of GSK-3beta, but also by the oral administration of lithium chloride. In addition, the GSK-3beta insufficiency caused an increased bone mass in adult mice without other abnormalities. A previous study has revealed that the lithium chloride administration increased bone mass in normal C57BL/6 mice and osteoporosis model SAMP6 mice [24]. A recent report also showed that oral administration of LY603281-31-8, a small molecule inhibitor of GSK-3beta and GSK-3alpha, increased bone formation, density and strength in an ovariectomized rat model [13] to the levels comparable to teriparatide (human PTH1-34), the only osteoanabolic drug that has recently been introduced into clinical practice for osteoporosis patients [39]. Taken together, these observations strongly suggest that the GSK-3beta suppression may yield novel therapeutics to treat bone catabolic disorders like cleidocranial dysplasia and osteoporosis. Although characterization of small molecule inhibitors of GSK-3beta is still underway, safety issues have not been reported at least for lithium chloride which is widely used by patients to treat bipolar disorder [40]. Hopefully prospective clinical trials on these drugs will be successful and generate epochal therapeutics for skeletal disorders.
###end p 34
###begin title 35
Materials and Methods
###end title 35
###begin title 36
Animals
###end title 36
###begin p 37
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 145 148 142 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 153 158 150 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 162 165 156 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 71 75 <span type="species:ncbi:10090">mice</span>
###xml 166 170 <span type="species:ncbi:10090">mice</span>
Mice were maintained in a C57BL/6 background. In each experiment, male mice that were littermates generated from the intercross between Gsk-3beta+/+ and Gsk-3beta+/- mice were compared. All experiments were performed according to the protocol approved by the Animal Care and Use Committee of the University of Tokyo.
###end p 37
###begin title 38
Radiological and histological analyses
###end title 38
###begin p 39
###xml 1088 1092 1080 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Parfitt1">[41]</xref>
###xml 1322 1325 1314 1317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Komori1">[3]</xref>
###xml 680 684 <span type="species:ncbi:10090">mice</span>
###xml 1131 1136 <span type="species:ncbi:10090">mouse</span>
Plain radiographs were taken using a soft X-ray apparatus. Micro CT scanning was performed using a composite X-ray analyzer (NS-ELEX Inc.), and cross-sectional tomograms of 10 microm thickness were reconstructed at 12x12 pixels into a 3-D feature by the volume-rending method. For von Kossa and toluidine blue stainings, samples were fixed with 70% ethanol, embedded in glycol methacrylate without decalcification, and sectioned in 3 microm slices. Histomorphometric analyses were performed in the secondary spongiosa (1.0 mm in length from 0.3 mm below the growth plate) of the proximal tibias using an image analyzer. For double labeling to analyze the dynamic bone remodeling, mice were injected subcutaneously with 8 mg/kgBW of calcein at 10 d and 3 d before sacrifice. Tartrate resistant acid phosphatase (TRAP)-positive osteoclasts were stained at pH 5.0 in the presence of L(+)-tartaric acid using naphthol AS-MX phosphate in N,N-dimethyl formamide as the substrate. Histomorphometric measurements were performed in eight optical fields, according to the ASBMR nomenclature report [41], and the averages were calculated per mouse. Alizarin red and alcian blue stainings of the whole mount skeleton of neonates were performed after they were fixed in 100% ethanol and transferred to acetone, as described previously [3]. The specimens were kept in 20% glycerol-1% KOH until the skeletons became clearly visible.
###end p 39
###begin title 40
Osteoclast formation assay
###end title 40
###begin p 41
###xml 156 160 156 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Ogata1">[11]</xref>
###xml 162 166 162 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Akune1">[12]</xref>
###xml 257 258 257 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 298 299 298 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 332 337 332 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 341 344 338 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 348 353 345 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 357 360 351 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 422 423 408 409 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 424 425 410 411 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 453 454 439 440 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 53 57 <span type="species:ncbi:10090">mice</span>
###xml 126 130 <span type="species:ncbi:10090">mice</span>
Osteoblasts were isolated from calvariae of neonatal mice, and bone marrow cells were collected from long bones of 8-week-old mice, as previously described [11], [12]. TRAP-positive multinucleated osteoclasts were generated by co-culturing osteoblasts (1x104 cells/well) and bone marrow cells (5x105 cells/well) derived from either Gsk-3beta+/+ or Gsk-3beta+/- littermates in alphaMEM containing 10% FBS with 1alpha,25(OH)2D3 (10 nM) and prostaglandin E2 (100 nM) for 6 days. Cells positively stained for TRAP and containing more than three nuclei were counted as osteoclasts.
###end p 41
###begin title 42
Osteoblast cultures
###end title 42
###begin p 43
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 307 308 296 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
Isolated calvaria osteoblasts were inoculated at a density of 2x105 cells/well onto 24-well plates in alphaMEM containing 50 microg/ml ascorbic acid, 10 mM beta-glycerophosphate, and ITS+1 liquid media supplement (Sigma-Aldrich) (osteogenic medium). For cell proliferation assay, cells were inoculated at 103 cells per well in a 96-well plate and cultured for 8 days in the osteogenic medium with cell sampling every day. The proliferation of cells was quantified using an XTT {sodium 3,3-[(phenylamino) carbonyl]-3,4-tetrazolium-bis (4-methoxy-6-nitro) benzenesulfonic acid hydrate} Assay Kit (Roche). The absorbance of the product was quantified using a MTP-300 microplate reader (Corona Electric) read at 450 nm with reference wavelength 630 nm. The adenovirus vector carrying GFP, GSK-3beta, CA- GSK-3beta, KI- GSK-3beta, or Runx2 gene was constructed using the Adeno-X Expression System (BD Biosciences), and was infected at 50 multiplicity of infection (MOI). The total MOI in each well was adjusted to be equal with the adenovirus encoding GFP. Two weeks after confluency, the total RNA was extracted, and the ALP, Alizarin red and von Kossa stainings were performed. For the ALP staining, cells were fixed in 70% ethanol and stained for 10 min with a solution containing 0.01% naphtol AS-MX phosphate disodium salt, 1% N, N-dimethyl-formamide, and 0.06% fast blue BB. For the Alizarin red staining, cells were fixed in 10% formalin/PBS and stained with 2% Alizarin red S (pH 4.0) solution. For the von Kossa staining, cells were fixed with 100% ethanol, stained with 5% silver nitrate solution under ultraviolet light, and incubated with 5% sodium thiosulfate solution (Wako).
###end p 43
###begin title 44
Real-time RT-PCR
###end title 44
###begin p 45
###xml 237 240 <span type="species:ncbi:11866?0.5863095238095238|species:ncbi:12321?0.21726190476190477">AMV</span>
###xml 699 704 <span type="species:ncbi:9606">human</span>
###xml 755 760 <span type="species:ncbi:10090">mouse</span>
The total RNA was extracted using an ISOGEN Kit (Wako) and an RNeasy Mini Kit (QIAGEN), and treated with DNaseI (QIAGEN), according to the manufacturers' instructions. One microg of RNA was reverse-transcribed with a Takara RNA PCR Kit (AMV) ver.2.1 (Takara) to generate single-stranded cDNA. PCR was performed with an ABI Prism 7000 Sequence Detection System (Applied Biosystems). Each PCR reaction consisted of 1 X QuantiTect SYBR Green PCR Master Mix (QIAGEN), 0.3 microM specific primers and 500 ng of cDNA. The mRNA copy number of a specific gene in total RNA was calculated using a standard curve generated by serially diluted plasmids containing PCR amplicon sequences, and normalized to the human or rodent total RNA (Applied Biosystems) with the mouse actin as an internal control. The standard plasmids were synthesized using a TOPO TA Cloning Kit (Invitrogen), according to manufacturer's instructions. All reactions were run in triplicate. Primer sequences are available upon request.
###end p 45
###begin title 46
Immunoblot and immunoprecipitation assays
###end title 46
###begin p 47
###xml 701 706 <span type="species:ncbi:10090">mouse</span>
###xml 728 734 <span type="species:ncbi:9986">rabbit</span>
Proteins were extracted with an M-PER or NE-PER Kit (Pierce Chemical), according to the manufacturer's instructions. Protein concentrations of cell lysates were measured using a Protein Assay Kit II (BIO-RAD). For immunoblot analysis, lysates were fractionated by SDS-PAGE with 4-20% Tris-Glycin gradient gel or 18% Tris-Glycin gel (Invitrogen) and transferred onto nitrocellulose membranes (BIO-RAD). After being blocked with 6% milk/TBS-T, membranes were incubated with an antibody to GSK-3alpha (Cell Signaling), to GSK-3beta (Cell Signaling), to Runx2 (MBL), to HA tag (Upstate), to FLAG tag (Sigma-Aldrich), or to beta-actin (Sigma-Aldrich). As secondary antibodies, HRP-conjugated antibodies to mouse IgG (Promega) and to rabbit IgG (Promega) were used. Immunoreactive bands were visualized with ECL Plus (Amersham), according to the manufacturer's instructions. Immunoprecipitation was performed using antibodies either noncovalently bound or conjugated to protein G-Sepharose (GIBCO). Equivalent amounts (20 microg) of cell lysate were immunoprecipitated with an antibodyb to Runx2 for 4 hours at 4degreesC. For co-immunoprecipitation (co-IP), cDNA encoding RUNX2 and GSK-3beta genes were sub-cloned into p3XFLAG-CMVtrade mark (Sigma-Aldrich) vector (3X FLAG-RUNX2) and pCMV-HA (Clontech) vector (HA-GSK-3beta), respectively. Supernatant of centrifuged cell lysate, collected using RIPA lysis buffer (150 mM NaCl, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 50 mM Tris, pH 8.0) from 293T cells transfected with 3X FLAG-RUNX2 and/or HA-GSK-3beta, was subjected to subsequent analysis. The co-IP complexes were recovered using EZviewtrade mark Red ANTI-FLAG(R) M2 Affinity Gel (Sigma-Aldrich) or ProFoundtrade mark HA Tag IP/Co-IP Kit (Pierce) according to the manufacturer's instruction.
###end p 47
###begin title 48
Luciferase reporter analysis and EMSA
###end title 48
###begin p 49
###xml 790 795 773 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 799 802 779 782 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 806 811 786 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 815 818 792 795 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8211;</sup>
###xml 1042 1046 1019 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Ducy2">[18]</xref>
Huh-7 cells were plated onto 24-well plates, and were transfected with 0.1 microg of the reporter constructs (1,050 OC-Luc) and 0.1 or 0.2 microg of the plasmids encoding wild-type or five kinds of phosphorylation-deficient mutants of Runx2, GSK-3beta, CA-GSK-3beta, or KI-GSK-3beta using FuGENE6 (Roche Diagnostics), and cultured for 2 days. The amount of total DNA in each well was adjusted to be equal with the pEGFP vector. The luciferase assay was performed using a PicaGene Dual SeaPansy Luminescence Kit (Toyo Ink) and Lumat LB 9507 (Berthold Technologies). The level of luciferase activity was normalized to the level of Renilla luciferase activity. EMSA was performed using a DIG Gel Shift Kit (Roche), according to the manufacturer's instructions. In brief, nuclear extracts from Gsk-3beta+/+ or Gsk-3beta+/- osteoblasts transfected with plasmid expressing wild-type Runx2, or HeLa cells transfected with wild-type or M(373)3 Runx2 were incubated with digoxigenin-labeled double-stranded oligo-dNT probes encoding the OSE2 sequence [18] and separated using non-denaturing PAGE, and the immunoreactivity for digoxigenin was visualized by chemiluminescence. For the competition experiment, 50-fold excess of unlabelled wild-type or the mutated OSE2 probe was added to the solution.
###end p 49
###begin title 50
In vitro kinase assay
###end title 50
###begin p 51
###xml 287 288 284 285 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 300 301 297 298 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 205 210 <span type="species:ncbi:9606">human</span>
Flag-wild-type Runx2 or Flag-M(373)3 Runx2 was prepared from the respective Runx2 overexpresssing HeLa cells by immunoprecipitation with an antibody to Flag. The immunoprecipitated protein and recombinant human GSK-3beta (Upstate) were mixed in a reaction buffer (20 mM HEPES, 10 mM MgCl2, 10 mM MnCl2, 1 mM dithiothreitol, and 0.2 mM EDTA) with 1.6 mM ATP, and incubated at 30degreesC for 30 min. Reaction products were analyzed by immunoblotting using an antibody to phosphoserine (CHEMICON).
###end p 51
###begin title 52
Rescue of cleidocranial dysplasia by suppressing GSK-3beta
###end title 52
###begin p 53
###xml 5 8 5 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Runx2<sup>+/&#8722;</sup></italic>
###xml 115 118 112 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 106 118 106 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3&#946;<sup>+/&#8722;</sup></italic>
###xml 123 128 120 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Runx2</italic>
###xml 128 131 125 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 191 196 188 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gsk-3</italic>
###xml 200 203 194 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 210 213 204 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 200 213 194 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>+/&#8722;</sup>; Runx2<sup>+/&#8722;</sup></italic>
###xml 270 275 264 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Runx2</italic>
###xml 275 278 269 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 545 549 539 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-Dixon1">[20]</xref>
###xml 551 555 545 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000837-DeSarno1">[21]</xref>
###xml 9 13 <span type="species:ncbi:10090">mice</span>
###xml 132 136 <span type="species:ncbi:10090">mice</span>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
###xml 561 565 <span type="species:ncbi:10090">mice</span>
###xml 827 831 <span type="species:ncbi:10090">mice</span>
Runx2+/- mice were kindly provided by T. Komori (Nagasaki University). For the genetic rescue, we crossed Gsk-3beta+/- and Runx2+/- mice to generate the compound heterozygous deficient mice (Gsk-3beta+/-; Runx2+/-), and compared the skeletal phenotypes of neonates with Runx2+/-. For the pharmacological rescue, we administered lithium chloride from E7.5 to 3 weeks of age before weaning through the pregnant and lactating dams by feeding with pelleted chow containing 4 mg/kg lithium chloride along with 1.5% NaCl water as previously described [20], [21]. The mice were euthanized for radiological analyses at 3 weeks. The quantitative analysis of the area of the anterior fontanelles and the length of the clavicles on the histology and X-ray were performed using an NIH Image. The serum lithium concentration of the treated mice was measured by an atomic absorption spectrophotometer (Hitachi).
###end p 53
###begin title 54
Statistical analysis
###end title 54
###begin p 55
###xml 116 124 114 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post-hoc</italic>
All data are means+/-SEMs. Means of groups were compared by ANOVA and significance of differences was determined by post-hoc testing using Bonferroni's method.
###end p 55
###begin p 56
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Runx2</italic>
###xml 28 31 28 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 32 36 <span type="species:ncbi:10090">mice</span>
###xml 61 65 <span type="species:ncbi:155640">Lian</span>
We thank T. Komori for Runx2+/- mice, and K. Miyazono and J. Lian for providing DNA constructs.
###end p 56
###begin title 57
References
###end title 57
###begin article-title 58
Reaching a genetic and molecular understanding of skeletal development.
###end article-title 58
###begin article-title 59
Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation.
###end article-title 59
###begin article-title 60
Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts.
###end article-title 60
###begin article-title 61
Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development.
###end article-title 61
###begin article-title 62
GSK-3: tricks of the trade for a multi-tasking kinase.
###end article-title 62
###begin article-title 63
Glycogen synthase kinase-3 in insulin and Wnt signalling: a double-edged sword?
###end article-title 63
###begin article-title 64
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.
###end article-title 64
###begin article-title 65
###xml 116 120 <span type="species:ncbi:10090">mice</span>
Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor.
###end article-title 65
###begin article-title 66
High bone density due to a mutation in LDL-receptor-related protein 5.
###end article-title 66
###begin article-title 67
A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait.
###end article-title 67
###begin article-title 68
Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover.
###end article-title 68
###begin article-title 69
Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts.
###end article-title 69
###begin article-title 70
Regulation of bone mass by Wnt signaling.
###end article-title 70
###begin article-title 71
Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation.
###end article-title 71
###begin article-title 72
A twist code determines the onset of osteoblast differentiation.
###end article-title 72
###begin article-title 73
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
###end article-title 73
###begin article-title 74
Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling.
###end article-title 74
###begin article-title 75
###xml 77 82 <span type="species:ncbi:10090">mouse</span>
Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene.
###end article-title 75
###begin article-title 76
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
###end article-title 76
###begin article-title 77
###xml 118 123 <span type="species:ncbi:10090">mouse</span>
Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex.
###end article-title 77
###begin article-title 78
Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium.
###end article-title 78
###begin article-title 79
Wnt signaling in osteoblasts and bone diseases.
###end article-title 79
###begin article-title 80
Regulation of osteoblastogenesis and bone mass by Wnt10b.
###end article-title 80
###begin article-title 81
###xml 107 111 <span type="species:ncbi:10090">mice</span>
Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice.
###end article-title 81
###begin article-title 82
Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis.
###end article-title 82
###begin article-title 83
Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes.
###end article-title 83
###begin article-title 84
Sequential roles of Hedgehog and Wnt signaling in osteoblast development.
###end article-title 84
###begin article-title 85
Regulation of skeletal development by the Runx family of transcription factors.
###end article-title 85
###begin article-title 86
Serine phosphorylation of RUNX2 with novel potential functions as negative regulatory mechanisms.
###end article-title 86
###begin article-title 87
###xml 38 41 <span type="species:ncbi:10116">rat</span>
Parathyroid hormone regulation of the rat collagenase-3 promoter by protein kinase A-dependent transactivation of core binding factor alpha1.
###end article-title 87
###begin article-title 88
MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1.
###end article-title 88
###begin article-title 89
Fibroblast growth factor 2 induction of the osteocalcin gene requires MAPK activity and phosphorylation of the osteoblast transcription factor, Cbfa1/Runx2.
###end article-title 89
###begin article-title 90
Runx2 phosphorylation induced by fibroblast growth factor-2/protein kinase C pathways.
###end article-title 90
###begin article-title 91
Molecular basis of tissue-specific gene expression mediated by the runt domain transcription factor PEBP2/CBF.
###end article-title 91
###begin article-title 92
Insulin like growth factors and the local regulation of bone formation.
###end article-title 92
###begin article-title 93
Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues.
###end article-title 93
###begin article-title 94
###xml 116 120 <span type="species:ncbi:10090">mice</span>
Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2.
###end article-title 94
###begin article-title 95
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature
###end article-title 95
###begin article-title 96
###xml 93 98 <span type="species:ncbi:9606">women</span>
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
###end article-title 96
###begin article-title 97
###xml 32 40 <span type="species:ncbi:9606">patients</span>
Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment.
###end article-title 97
###begin article-title 98
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.
###end article-title 98
###begin p 99
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 99
###begin p 100
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This study was supported by a Grant-in-aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science, and Technology (#17390410) and Terumo Life Science Foundation. The sponsor had no role in study design, data collection, data analysis, data interpretation, or writing of the manuscript.
###end p 100

